MOH
Molina Healthcare, Inc.
MOH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MOH overall, supported by stronger fundamentals and stronger modeled upside.
MOH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
MOH's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MOH PE Valuation
MOH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MOH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for MOH, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MOH on the outlook, with more favorable profitability expectations.
MOH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.35 | — |
| Q3 2026 | -$0.60 | -104% |
| Q2 2026 | $0.18 | -99% |
| Q1 2026 | $3.74 | -82% |
| Q4 2025 | $8.92 | -56% |
| Q3 2025 | $16.14 | -18% |
| Q2 2025 | $20.28 | +11% |
| Q1 2025 | $20.70 | +12% |
| Q4 2024 | $20.42 | +8.8% |
MOH has swung to a loss: it lost $0.60 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MOH on earnings quality, reporting a profit while its opponent remains loss making.
MOH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.1B | -3.4% |
| Q2 2026 | $10.9B | -4.8% |
| Q1 2026 | $10.8B | -3.1% |
| Q4 2025 | $11.4B | +8.3% |
| Q3 2025 | $11.5B | +11% |
| Q2 2025 | $11.4B | +16% |
| Q1 2025 | $11.1B | +12% |
| Q4 2024 | $10.5B | +16% |
MOH's revenue grew through 2024 and has held roughly level since: $11.1B last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1% | -0.2 points |
| Q2 2026 | 1.3% | -1.9 points |
| Q1 2026 | 0.8% | -3.1 points |
| Q4 2025 | -1.4% | -5 points |
| Q3 2025 | 1.2% | -3.3 points |
| Q2 2025 | 3.3% | -1.1 points |
| Q1 2025 | 3.9% | -0.4 points |
| Q4 2024 | 3.6% | +0.1 points |
MOH's operating margin was 1% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MOH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MOH on profitability, with a higher operating margin.
MOH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$196M | -$33M |
| Q2 2026 | -$324M | +$20M |
| Q1 2026 | $1.1B | +528% |
| Q4 2025 | -$297M | -$62M |
| Q3 2025 | -$163M | -119% |
| Q2 2025 | -$344M | -$98M |
| Q1 2025 | $168M | -10% |
| Q4 2024 | -$235M | +$450M |
MOH's free cash flow has turned positive after two years mostly in the red: $238M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MOH on cash flow, with more consistent year-over-year improvement.
MOH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +200K shares |
| 1 year | -1.9% | -1M shares |
| 3 years | -11% | -6.6M shares |
| 5 years | -12% | -7M shares |
| Available history | -20% | -12.7M shares |
MOH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $500M |
| Q2 2025 | — |
| Q1 2025 | $500M |
| Q4 2024 | $500M |
MOH hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MOH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -3.3x | Net Cash |
| Q1 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
MOH has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MOH on leverage, with a lower net debt burden relative to earnings.
MOH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 55.8 | Neutral |
MOH's weekly RSI is 56 (neutral) and its Stochastic is 56 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MOH PE vs Healthcare Sector
| Metric | MOH | Sector median | Relative |
|---|---|---|---|
| PE | 1,152x | 26x | 4,356% above |
| PE % | 100 | 29 | 71 pts above |
MOH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MOH on valuation relative to its sector.
MOH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $202.2 | 3.8% above |
| 20 week MA | $205.7 | 2% above |
| 50 week MA | $183.7 | 14% above |
| 100 week MA | $216.0 | 2.9% below |
| 200 week MA | $271.6 | 23% below |
MOH has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 23% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MOH on trend strength, trading above more of its moving averages.
MOH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $136.1 | $207.1 | +52% |
| 2021 | $207.1 | $316.7 | +53% |
| 2022 | $316.7 | $335.1 | +5.8% |
| 2023 | $335.1 | $361.3 | +7.8% |
| 2024 | $361.3 | $292.2 | -19% |
| 2025 | $292.2 | $164.8 | -44% |
| 2026 YTD | $164.8 | $209.9 | +27% |
MOH has finished higher in four of the last six years, two of them by more than 50%. It's up 27% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MOH on returns for 2026, with the stronger performance.